\
&
Contact us
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has recently published the first amendment to the Digital Europe Main Work Programme 2025-2027, taking into account the most recent political priorities of the Commission. Among the main changes, the programme will now contribute to the landmark AI Gigafactories initiative, set to accelerate the development of cutting... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.